• ONX-0914 (PR-957): Selective Immunoproteasome LMP7 Inhibi...

  2026-02-04

  ONX-0914 (PR-957) is a highly selective immunoproteasome inhibitor that targets the LMP7 subunit, offering robust blockade of cytokine production in vitro and in vivo. Use of ONX-0914 enables precise dissection of immunoproteasome function in autoimmune and inflammatory models, with proven efficacy in arthritis, diabetes, and colitis. This article details ONX-0914’s mechanism, evidence base, and best practices for laboratory and preclinical use.

• CB-5083: Selective p97 AAA-ATPase Inhibitor for Protein H...

  2026-02-03

  CB-5083 is a potent, selective, and orally bioavailable p97 inhibitor that disrupts protein homeostasis in cancer cells, leading to apoptosis and significant tumor growth inhibition. Its high selectivity for the second ATPase domain of p97 and strong in vivo efficacy in xenograft models make it a benchmark tool for multiple myeloma and solid tumor research.

• MLN2238: Translational Leverage of Reversible 20S Proteas...

  2026-02-03

  This thought-leadership article explores the advanced mechanistic insights and translational strategies surrounding MLN2238, a next-generation, reversible proteasome β5 subunit inhibitor. We detail its role in apoptosis induction, NF-κB pathway suppression, and emerging intersections with CREB signaling and proteotoxic stress responses. Integrating new evidence from recent literature and competitive workflows, we present actionable guidance for translational researchers targeting multiple myeloma, lymphoma, and bortezomib-resistant cancer models.

• HyperScribe T7 High Yield RNA Synthesis Kit: Precision RN...

  2026-02-02

  The HyperScribe™ T7 High Yield RNA Synthesis Kit streamlines high-yield, customizable RNA production for applications spanning RNA vaccine research to ribozyme biochemistry. Its robust T7 RNA polymerase-driven transcription delivers consistent, high-quality RNA—whether capped, biotinylated, or dye-labeled—empowering breakthroughs in both basic and translational science. Explore how this APExBIO kit enhances workflow efficiency, troubleshooting, and experimental versatility.

• CB-5083: Advanced Insights into p97 Inhibition and ER Qua...

  2026-02-02

  Discover how CB-5083, a selective p97 inhibitor, enables next-generation research into protein homeostasis disruption, ER quality control, and cancer cell apoptosis. This article delivers a unique, in-depth analysis that integrates recent mechanistic discoveries and translational advances.

• MLN2238: Selective Reversible 20S Proteasome β5 Inhibitor...

  2026-02-01

  MLN2238 is a potent, reversible inhibitor of the 20S proteasome β5 subunit, validated for chymotrypsin-like proteasome inhibition in multiple myeloma and lymphoma research. Its nanomolar activity extends to bortezomib-resistant models and proteotoxic stress studies, offering a precise tool for apoptosis induction and pathway analysis. This article details its mechanism, benchmarks, and optimal laboratory use.

• Optimizing Cancer Cell Assays with CB-5083: Practical Sce...

  2026-01-31

  This in-depth article guides biomedical researchers through real-world scenarios where CB-5083 (SKU B6032) enhances assay reproducibility and mechanistic clarity. Drawing on quantitative data and recent literature, it demonstrates how this selective p97 inhibitor from APExBIO advances workflows in cell viability, apoptosis, and protein homeostasis research.

• Epoxomicin (SKU A2606): Data-Driven Solutions for Proteas...

  2026-01-30

  This authoritative guide addresses real-world laboratory challenges in ubiquitin-proteasome pathway research, focusing on experimental reproducibility, data interpretation, and product reliability. By exploring practical Q&A scenarios, the article demonstrates how Epoxomicin (SKU A2606) from APExBIO empowers biomedical researchers to achieve reliable results in cell viability, proliferation, and cytotoxicity assays.

• Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP): Innovations ...

  2026-01-30

  Explore how Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) advances bioluminescent reporter assays through optimized stability, immune evasion, and cutting-edge delivery strategies. Uncover new scientific insights into mRNA formulation and transfection potency beyond current literature.

• Decoding Proliferation: Mechanistic Insights and Strategi...

  2026-01-29

  This thought-leadership article guides translational researchers through the evolving landscape of cell proliferation analysis, leveraging mechanistic clarity, workflow innovation, and clinical relevance. By contextualizing the power of EdU Imaging Kits (Cy3) within modern DNA synthesis detection and referencing breakthrough findings in osteosarcoma resistance biology, the article offers an integrated blueprint for experimental design, assay selection, and future translational impact.

• MG-132 (SKU A2585): Scenario-Driven Solutions for Reliabl...

  2026-01-29

  This authoritative guide presents realistic laboratory scenarios where MG-132 (SKU A2585) addresses persistent challenges in apoptosis, cell cycle, and oxidative stress assays. Leveraging evidence-based insights, the article demonstrates how this cell-permeable proteasome inhibitor peptide aldehyde enables reproducible workflows, robust data, and informed vendor selection for biomedical researchers and lab technicians.

• Firefly Luciferase mRNA: Optimized Reporter for Gene Expr...

  2026-01-28

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) delivers robust, low-immunogenicity bioluminescent reporting in gene expression and cell viability assays. Its advanced chemical modifications and ARCA capping empower researchers with stable, reproducible signal—even in challenging in vitro and in vivo settings. Discover how to maximize experimental power while minimizing troubleshooting headaches.

• MLN2238: Advanced Proteasome β5 Subunit Inhibitor Workflows

  2026-01-28

  MLN2238 enables researchers to dissect proteasomal regulation in multiple myeloma, lymphoma, and bortezomib-resistant models with unmatched selectivity and reversibility. This guide details stepwise protocols, advanced applications, and troubleshooting strategies, empowering innovative research on apoptosis, NF-κB suppression, and the ROS/JNK/CREB axis.

• CB-5083: Unraveling Proteostasis and Lipid Homeostasis in...

  2026-01-27

  Explore how CB-5083, a selective oral p97 inhibitor, offers an advanced platform for dissecting the intersection of protein degradation and ER lipid regulation in cancer models. This article uniquely integrates mechanistic insights and translational applications, expanding beyond existing reviews.

• Epoxomicin: Unveiling Proteasome Inhibition in Complex Ce...

  2026-01-27

  Discover how Epoxomicin, a powerful selective 20S proteasome inhibitor, is redefining ubiquitin-proteasome pathway research by enabling advanced exploration of protein degradation, ER stress, and cellular quality control. This article uniquely synthesizes molecular insights, comparative strategies, and future research directions.

16105 records 4/1074 page Previous Next 12345 下5页 Last page